Europe's last penicillin plant in Kundl faces an uncertain future

The Sandoz facility in Kundl, Tyrol, faces an uncertain future as it struggles against significantly lower production costs in China. This site represents Europe’s last fully integrated penicillin plant, manufacturing the antibiotic from raw materials through to the final product. Plant manager Stephanie Jedner told Reuters that if the location were forced to close, Europe would become completely dependent on China for this vital medication. The pressure stems from Chinese competitors producing identical antibiotics and active ingredients at much lower prices. While these low costs benefit public health systems, they simultaneously threaten the viability of the Austrian factory. Several rivals have already announced plans to halt production or shift operations to China, placing Kundl at the center of a debate regarding European supply security. Just three years after a costly expansion project, Sandoz has requested an anti-dumping investigation from the European Commission. Such an inquiry could result in punitive tariffs on Chinese goods. The recent expansion cost 200 million euros, with 50 million euros coming from public funds. Penicillin remains one of the most critical classes of antibiotics for treating life-threatening infections, more than a century after its discovery by Alexander Fleming. However, China now dominates the manufacture of active ingredients used in approximately 1.5 billion daily doses administered annually in Europe. According to Eurostat data, China’s share of EU imports for penicillin and its derivatives, typically supplied as pharmaceutical active ingredients, nearly doubled from 44 percent in 2019 to 86 percent in the previous year. Concurrently, European exports of these substances have shrunk to less than one fifth of their peak levels recorded in the early 2000s. Earlier this year, Sandoz warned British parliamentarians that production in Kundl was economically unsustainable if governments did not pay more for penicillin. The company stated that Beijing’s control over the supply chain poses an inherent strategic risk comparable to that associated with critical minerals. In that statement, Sandoz noted that antibiotic supplies could potentially serve as a tool for economic coercion or hybrid warfare, particularly during periods of diplomatic tension. China has established itself as a reliable supplier of essential medicines over many years. Sandoz reports that up to 90 percent of global antibiotic active ingredients are currently produced outside Europe, primarily in China or India, where Chinese chemicals are also utilized. A US insider indicated that Chinese government representatives had hinted in discussions that Beijing might wield this market power as a weapon in trade conflicts. The Chinese Foreign Ministry rejected accusations of protectionism, stating that economic differences can be resolved through dialogue. The US State Department was initially unavailable for comment. Europe’s vulnerability in drug supply became evident in 2022 when stocks of amoxicillin, a penicillin variant manufactured in Kundl, ran low during a wave of respiratory infections. Following repeated shortages, the European Commission approved 28.3 million euros for the plant's expansion the following year. This investment increased production capacity by 20 percent. Historically, China relied heavily on Europe for penicillin production for decades after Fleming’s discovery. China analyst Tim Ruhl explained that roles have reversed due to massive industrial investments by Beijing. Experts attribute China’s dominance to laxer environmental regulations, significantly lower labor costs, and state subsidies. Sandoz accuses China of flooding the market with cheap, state-subsidized active ingredients. The company argues that the current pricing structure makes local production difficult to maintain despite the strategic importance of keeping manufacturing within Europe. The potential outcome of the requested anti-dumping probe will determine whether protective measures are implemented to shield the remaining European production base. The situation highlights the shifting dynamics in global pharmaceutical manufacturing and the growing concerns over dependency on non-European suppliers for critical healthcare inputs.